Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00940771 · ClinicalTrials.gov registry record · Phase 4

Equivalence of Boosted Atazanavir Based Regimens and Currently Effective HAART Regimens

A Phase 4 study of HIV Infections and Pediatric HIV, sponsored by Phoenix Children's Hospital.

Completed
Registry status
Phase 4
Development phase
10
Enrollment target
1
Study location

NCT00940771: Completed Phase 4 study of HIV Infections and Pediatric HIV, sponsored by Phoenix Children's Hospital.

NCT00940771 is a Phase 4 study of HIV Infections and Pediatric HIV that has completed, run by Phoenix Children's Hospital. The registered enrollment target is 10 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00940771, a Phase 4 study of HIV Infections and Pediatric HIV, has completed, sponsored by Phoenix Children's Hospital.

COMPLETED
Registry status
Phase 4
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

The hypothesis for this study is whether a treatment regimen containing Atazanavir in combination with Ritonavir will work as well as other regimens containing a protease inhibitor and/or a Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) at controlling HIV disease in children who are HIV+ and have high cholesterol or high triglycerides. . In this study, children who have high cholesterol or high triglycerides as a result of their HIV medicines, will have the PI or NNRTI in their medication regimen changed to Atazanavir, which is a PI in combination with a low dose of Ritonavir (another PI). Atazanavir has been shown in adults to result in lower cholesterol and triglycerides than other PI's and NNRTI's. The dose of Atazanavir and Ritonavir will be according to the Package Insert for this drug that is FDA approved for children. They will continue taking the other medications from the pre-study regimen. Children will take study drug for 24 weeks, and will be able to continue study drug after the study using commercially available drug. Lab tests and a physical exam will be undertaken at 4 weeks, 12 weeks and 24 weeks after starting study drug to determine how effective the new drug is and to monitor for possible side effects.

Interventions

  • DRUG Boosted Atazanavir

Study Locations (1)

Arizona

  • Phoenix Children's Hospital - Phoenix

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2009-08-26
Est. Completion 2016-11-23
Phase Phase 4
Phoenix Children's Hospital

26 total trials

What the finished NCT00940771 record still lists

NCT00940771 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (98% lower).

The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Boosted Atazanavir is the first listed.

NCT00940771 reports a single indexed study location in Arizona.

Frequently Asked Questions

What is clinical trial NCT00940771 about?

NCT00940771 is a clinical study titled "Equivalence of Boosted Atazanavir Based Regimens and Currently Effective HAART Regimens". The hypothesis for this study is whether a treatment regimen containing Atazanavir in combination with Ritonavir will work as well as other regimens containing a protease inhibitor and/or a Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) at controlling HIV disease in children who are HIV+ and...

What is the current status of trial NCT00940771?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2009-08-26. Estimated completion is 2016-11-23.

What conditions does trial NCT00940771 study?

This clinical trial studies the following conditions: HIV Infections, Pediatric HIV.

What interventions are being tested in trial NCT00940771?

The interventions under investigation include: Boosted Atazanavir (DRUG).

Who is sponsoring clinical trial NCT00940771?

This trial is sponsored by Phoenix Children's Hospital, which has 26 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00940771 being conducted?

This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00940771's enrollment target sits among peer trials

10 526th of 542 higher than 14 of 542 other HIV Infections trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00623389 · 10 participants · NA

    Evaluation of an Advanced Lower Extremity Neuroprostheses

  • NCT01241864 · 10 participants · Phase 2

    Islet Transplantation in Type 1 Diabetic Kidney Allograft

  • NCT01293214 · 10 participants · NA

    Vascularized Composite Allotransplantation for Multiple Extremity Amputations

  • NCT01474148 · 10 participants · NA

    A Neuroprosthesis for Seated Posture and Balance

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00940771, the US trial registry maintained by the National Library of Medicine. NCT00940771 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.